# A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

> **NCT05792410** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- HER2 Low Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** SHR-A1811 & Dalpiciclib Isethionate Tablets
- **DRUG:** SHR-A1811 & Fulvestrant
- **DRUG:** SHR-A1811 & Bevacizumab injection

## Key facts

- **NCT ID:** NCT05792410
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04
- **Primary completion:** 2024-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2023-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05792410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05792410, "A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05792410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*